Retrospective review 2006–2019

Coronary artery bypass grafting surgery
(n = 84.750)

Exclusion
- baseline heart rhythm not AF or not reported
- single vessel CAD
- concomitant procedures
- number of distal anastomoses and/or type of grafts could not be determined
- non-complete revascularization
- <18 y.o.

Coronary artery bypass grafting surgery for MV CAD with complete revascularization and AF (n = 4.746)

Total arterial revascularization
(n = 295)

Non total arterial revascularization
(n = 4.451)

PS matching

Total arterial revascularization
(n = 295)

Non total arterial revascularization
(n = 295)

Median follow-up 4.1 years (max. 15.1 years)

**Figure S1.** Study flow-chart

Figure S2. SMDs between TAR and non-TAR before and after PS matching

Table S1. Preoperative characteristics before and after PS-matching

Variable	All patients			
	Total (4746)	**Non TAR (4451)**	**TAR (295)**	***P*-value**
Baseline characteristics				
Age years, median (IQR)	69 (63–75)	70 (63–75)	68 (62–74)	<0.001
Male gender	3669 (77.3%)	3,441 (77.3%)	228 (77.3%)	>0.99
EuroSCORE, median (IQR)	1.32 (0.87–2.32)	1.32 (0.87–2.32)	1.31(0.83–2.33)	0.02
Diabetes	1969 (41.5%)	1853 (41.6%)	116 (39.3%)	0.46
Insulin ± oral hypoglycemic drugs	782 (16.5%)	730 (16.4%)	52 (17.6%)	0.57
Smoking	2927 (61.7%)	2732 (61.4%)	195 (66.1%)	0.11
Hypertension	4299 (90.6%)	4037 (90.7%)	262 (88.8%)	0.30
Hyperlipidemia	3134 (66.0%)	2955 (66.4%)	179 (60.7%)	0.049
Poor mobility[a]	246 (5.2%)	233 (5.2%)	13 (4.4%)	0.68
BMI (median [IQR])	28.40 (25.71–31.40)	28.39 (25.71–31.44)	28.72 (26.26–30.58)	0.70
Pulmonary hypertension*	225 (4.7%)	215 (4.8%)	10 (3.4%)	0.32
Severe (PA systolic >55 mmHg)*	18 (0.4%)	18 (0.4%)	0 (0%)	0.62
Renal impairment*	1401 (29.5%)	1318 (29.6 %)	83 (28.1%)	0.65
Dialysis (regardless of CC)*	26 (0.6%)	26 (0.6%)	0 (0%)	0.40
Peripheral artery disease	735 (15.5%)	698 (15.7%)	37 (12.5%)	0.16
Cerebrovascular disease	491 (10.3%)	471 (10.6%)	20 (6.8%)	0.04
History of stroke	188 (4.0%)	181 (4.1%)	7 (2.4%)	0.17
History of TIA	197 (4.2%)	188 (4.2%)	9 (3.05%)	0.45
Chronic lung disease	408 (8.6%)	376 (8.5%)	32 (10.9%)	0.16
LVEF (%) (median [IQR])*	50 (40–55)	50 (40–55)	50 (40–55)	0.10
3 vessel CAD	2791 (58.8%)	2667 (59.9%)	124 (42.0%)	<0.001
LM disease	1477 (31.1%)	1400 (31.5%)	77 (26.1%)	0.06
Previous MI	2637 (55.6%)	2484 (55.8%)	153 (51.9%)	0.20
Previous PCI	1068 (22.5%)	992 (22.4%)	76 (25.8%)	0.17
NYHA IV	139 (2.9%)	132 (3.0%)	7 (2.4%)	0.72
CCS 4	574 (12.1%)	549 (12.3%)	25 (8.5%)	0.05
ACS	137 (2.9%)	123 (2.8%)	12 (4.1%)	0.10

[a]Missing data

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CC, creatinine clearance; CCS, Canadian Cardiovascular Society; IQR, interquartile range; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PA, pulmonary artery; PCI, percutaneous coronary intervention; PS, propensity score; TIA, transient ischemic attack; VD, vessel disease

Figure S3. LIMA-LAD vs. SVG-LAD. Unadjusted survival curves between the two groups: LIMA-LAD vs. SVG-LAD CABG for the analysis of long-term survival. Hazard ratios and respective 95% confidence intervals in LIMA-LAD as compared to SVG-LAD CABG